Association between syndesmophyte and metabolic syndrome in patients with psoriatic arthritis or ankylosing spondylitis: a cross-sectional study

Chonachan Petcharat 1, Varalak Srinonprasert 2 and Praveena Chiowchanwisawakit 1*

Abstract

Objective: To investigate the prevalence of and factors associated with metabolic syndrome (MetS) in patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS).

Methods: This cross-sectional study included PsA or AS patients who attended Siriraj Hospital (Bangkok, Thailand) during March 2014 to October 2017. The Harmonized MetS definition was used to diagnose MetS. Demographic, clinical, and spinal radiographic data were collected. Logistic regression was used to identify factors associated with MetS.

Results: Among 319 patients, 153 had AS and 166 had PsA. MetS was present in 43% of PsA and 19% of AS (p < 0.001). Multiple regression analysis identified body mass index (BMI) > 23 (odds ratio [OR]: 3.7), female gender (OR range: 3.8–3.9), and the number of syndesmophytes or ankylosis [SynAnk] (OR: 1.1) were associated with MetS among PsA patients. For AS patients, BMI > 23 (OR: 9.1) and age ≥ 40 (OR: 4.3) were associated with MetS. Disease activity index was not associated with MetS.

Conclusions: MetS was significantly more prevalent in PsA than in AS. Structural change of the spine was associated with MetS in PsA. PsA patients with being female, BMI > 23 or evidence of spinal change should be informed to screen for MetS. AS patients with age ≥ 40 or BMI > 23 should be informed to screen for MetS.

Keywords: Prevalence, Factors, Metabolic syndrome, Psoriatic arthritis, Ankylosing spondylitis, Cross-sectional study

Introduction

Spondyloarthritis (SpA) comprises a group of chronic inflammatory rheumatic diseases, including ankylosing spondylitis (AS) and psoriatic arthritis (PsA) [1]. Chronic systemic inflammation and cardiovascular disease (CVD) [2] are thought to have a common inflammatory pathogenesis that is not clearly understood. Metabolic syndrome (MetS) is defined as a cluster of classical and modifiable cardiovascular risk factors, including insulin resistance, central obesity, elevated blood pressure, high triglyceride levels, and low levels of high-density lipoprotein cholesterol (HDL-C) [3]. Individuals with MetS are at increased risk of developing CVD over the following 5 to 10 years [3]. MetS may also be an important risk factor for CVD in patients with chronic inflammatory arthritis [4]. Chronic inflammatory joint disease, especially rheumatoid arthritis, may also be an important factor that relates to CVD [5]. Subclinical atherosclerotic disease has been reported in patients with PsA or AS [6, 7].

* Correspondence: praveena.chi@mahidol.ac.th
1Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoken, Bangkok 10700, Thailand
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Published systematic reviews and meta-analyses concluded that the prevalence of CVD is increased in PsA patients (odds ratio [OR] 1.6) [8], and in AS patients (OR: 1.5–1.6) [9] when compared with the general population. However, heterogeneous study designs and varying cardiovascular outcome criteria raise concerns about potential biases [8–10]. The increased risk of CVD in PsA and AS may be due to chronic joint inflammation, traditional risk factors for CVD, or both [11]. Furthermore, chronic inflammatory joint disease and MetS are believed to share a common inflammatory pathogenesis [12, 13].

Several studies reported the prevalence of MetS to be higher in patients with PsA (38.0 to 59.0%) than in general population [10, 14–17]. Similarly, other studies reported the prevalence of MetS in patients with AS to be 11 to 45% [15, 18, 19]. This observed variability in prevalence estimates may be explained by the use of different MetS definitions, ethnicities, lifestyles, types of inflammatory disease, and treatments for chronic rheumatic disease. There have been few published reports focusing on MetS in PsA patients and AS patients in Asia, and there have been none from Thailand. Accordingly, the aim of this study was to investigate the prevalence of and factors associated with MetS in patients with PsA or AS at Siriraj Hospital – Thailand’s largest national tertiary referral center.

Materials and methods

Patients

This cross-sectional study enrolled patients older than 18 years that were diagnosed with AS according to Modified New York criteria [20], or diagnosed with PsA according to the classification criteria for psoriatic arthritis [21], and that had visited the outpatient clinics of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand during the 15 March 2014 to 31 October 2017 study period. Siriraj Hospital is a 2300-bed national tertiary center, and Thailand’s largest teaching hospital. Patients unwilling to be assessed for MetS and those with symptomatic infection were excluded. Written informed consent was obtained from all participants. The protocol for this study was approved by the Siriraj Institutional Review Board (SIRB) (COA no. Si 147/2014) on 14 March 2014, and complied with the Declaration of Helsinki 1964 and all of its later amendments.

Clinical and laboratory assessments

Demographic data, disease duration, history of comorbidities (hypertension, diabetes, dyslipidemia, cardiovascular disease, and cerebrovascular disease), occupation, smoking status (current smoker, ex-smoker, or never-smoked), current use of non-steroidal anti-inflammatory drugs (NSAIDs) and/or disease modifying anti-rheumatic drugs (DMARDs), current habitual exercise, and scores from the Thai versions of patient self-reported outcome assessments were collected, recorded, and analyzed. The aforementioned outcome assessments included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [22], Patient Global Assessment (PGA), and the Patient Pain (PP) assessment, which is a numerical scale from 0 (no pain) to 10 (very severe pain). Occupation was divided into physical and non-physical work.

Physical examination of peripheral joints (66 swollen/68 tender joint counts) and dactylitis were assessed by one rheumatologist (PC or CP). Body weight, height, waist circumference (WC), and blood pressure (BP) were collected. WC was measured at the midpoint between the lower margin of the last rib and the top of the iliac crest while standing, and at the end of normal expiration. If elevated BP (systolic ≥ 130 and/or diastolic ≥ 85 mmHg) was identified, participants were asked to rest in a seated position for 10 min, and then the BP measurement was repeated. All physical examinations were performed regardless of questionnaire and blood test results. Blood was drawn after 12 h of fasting to determine fasting glucose (FG), triglycerides (TG), HDL-C, and C-reactive protein (CRP). CRP was tested by particle-enhanced immunoturbidimetric assay (cobas c502 module, cobas 8000 modular analyzer series, Roche Diagnostics International Ltd., Rotkreuz, Switzerland) (normal range: 0–5 mg/L).

Body mass index (BMI) was calculated as weight/height² (kg/m²), and 23 kg/m² (BMI ≥ 23) was determined to be the threshold for overweight status in Asian population [23]. The Ankylosing Spondylitis Disease Activity Score–C-reactive protein (ASDAS-CRP) calculation included PGA, BASDAI questions 2, 3, and 6, and CRP [24]. The Disease Activity Index for Psoriatic Arthritis (DAPSA) was based on the summation of 68 tender joint count (TJC), 66 swollen joint count (SJC), PGA, PP, and CRP (mg/dl) [25]. The Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) included all of items in the DAPSA with the exception of CRP [26].

Lateral views of cervical and lumbar spine radiographs taken within 2 years were included. The presence or absence of syndesmophyte or ankylosis at each corner from lower corner of the second cervical vertebrae to the upper corner of the first thoracic spine vertebrae, and from lower corner of the twelfth thoracic vertebrae to the upper corner of the first sacral spine was recorded. Syndesmophyte was defined as bone growth originating from the vertebral endplate in the anterior one-quarter of the discovertebral space, or from the anterior vertebral cortex [27]. Ankylosis was defined as the presence of bridging between the anterior vertebral
cortices or between vertebral end plates in the anterior quarter of the discovertebral space [27]. The assessment for syndesmophyte and ankylosis was performed by an experienced rheumatologist (PC) who was blinded to patient clinical data, who completed the Spondyloarthritis Radiography training module (http://www.carearthritis.com/spar/), and who had an excellent intraclass correlation coefficient with expert #1 (0.98, 95% confidence interval [CI]; 0.96–0.99), and expert #2 (0.93, 95% CI: 0.82–0.97).

**Definition of metabolic syndrome**

The presence of MetS was determined according to the Harmonized definition (2009) [3] that assigns the diagnosis if a patient meets at least three of the following five criteria: 1) WC ≥ 90 cm in males or ≥ 80 cm in females; 2) SBP ≥ 130 and/or diastolic blood pressure (DBP) > 85 mmHg, or receiving antihypertensive drug treatment in a patient with a history of hypertension; 3) elevated FG > 100 mg/dL or receiving drug treatment for elevated glucose; 4) elevated TG ≥ 150 mg/dL or receiving drug treatment for elevated triglycerides (fibrates, nicotinic acid, high-dose omega-3 fatty acids); and/or, 5) reduced HDL-C < 40 mg/dL in males or < 50 mg/dL in females, or receiving drug treatment for reduced HDL-C (fibrates, nicotinic acid).

**Statistical analysis**

Continuous variables were compared using Student’s t-test or Mann-Whitney U test, and those results are shown as mean ± standard deviation for normally distributed data or median and interquartile range for non-normally distributed data. Categorical variables were compared using Pearson’s χ² test or Fisher’s exact test, and those results are given as frequency and percentage. A p-value of less than 0.05 was considered statistically significant. Imputation was not conducted for missing data. Patients with an ASDAS-CRP score of 2.1 or greater (ASDAS-CRP ≥2.1) were considered to have a high level of disease activity [24]. A DAPSA score of more than 14 (DAPSA > 14), and a cDAPSA score of more than 13 (cDAPSA > 13) were considered to have moderate to high disease activity [28].

Univariate logistic regression analysis was used to determine association between evaluated factors and MetS. Variables with a p-value less than 0.2 and variables of interest, including smoking, disease duration, and disease activity index, were included in multiple regression analysis. Enter method was applied in fitting a multiple logistic regression model to determine effect of each factor adjusted for other factors in the model. To prevent multicollinearity in multiple regression analysis, only one disease activity index (ASDAS-CRP, DAPSA, or cDAPSA) was included in each model and multicollinearity was checked using variance inflation factor of less than 10. Statistical analyses were performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA).

**Results**

**Study population characteristics**

A total of 319 (153 AS and 166 PsA) participants were recruited for this study. The mean age of patients was 45.5 ± 12.2 years, and 148 (46.4%) were female. Two patients with PsA did not have a BASDAI assessment. A total of 295 (146 AS and 149 PsA) patients had spinal imaging, and 246 (114 AS, 132 PsA) patients had CRP performed. Fifteen (4 AS and 11 PsA) patients were treated with tumor necrotic factor alpha inhibitor (TNFi). Eight (4 AS and 4 PsA) patients were treated with oral prednisolone. PsA patients were significantly older, had higher BMI, and were more likely to be female, have a history of hypertension, have type 2 diabetes mellitus, have dyslipidemia, have occupational physical work, and have a shorter disease duration than AS patients (Table 1). The proportion of smoking, current NSAID use, the mean ASDAS-CRP, the median number of spinal corners having syndesmophyte or ankylosis per patient (SynAnk), and current DMARDs use were similar between patients with PsA and AS.

**Prevalence of MetS and characteristics of patients with MetS**

Patients with PsA had significantly higher proportions of all MetS components, including increased WC (p = 0.001), elevated BP (p < 0.001), elevated FG (p < 0.001), elevated TG (p = 0.01), and decreased HDL-C (p = 0.016) when compared to AS patients (Table 2). The prevalence of MetS was 31.7% for all participants, 43.4% for patients with PsA, and 19% among patients with AS (p < 0.001). Five patients with PsA had personal history of CVD, and two of those had MetS.

Among all study participants, patients with MetS were more likely to be older, female, to have higher BMI, and to have a higher number of SynAnk than those without MetS. Disease duration, ASDAS-CRP, the number of current DMARDs, and the proportion of NSAIDs uses were not significantly different between those with and without MetS. Many of the same associations were observed in subgroup analysis that were observed when we analyzed data from the entire study cohort. However, in the PsA subgroup, participants that smoked were less likely to have MetS, and gender was not associated with MetS in patients with AS.

**Factors associated with MetS in patients with PsA**

Regarding PsA patients, age ≥ 40 (p < 0.001), BMI ≥ 23 (p < 0.001), and the number of SynAnk (p = 0.001) were associated with MetS in univariate analysis. The disease...
activity index \([\text{cDAPSA} > 13 (p = 0.331), \text{DAPSA} > 14 (p = 0.230)]\) was not associated with MetS (Table 3). However, female gender \((p = 0.009)\) and smoking status \((p = 0.041)\) were also significantly associated with MetS in PsA patients. Factors that were significant in univariate analysis were further analyzed in multiple regression analysis. BMI \(>23 (p = 0.008)\) and female gender \((p = 0.007)\) were the two strongest associations with MetS. PsA patients with a higher number of SynAnk were more likely to be MetS \((p = 0.002)\). DAPSA was not as associated with MetS \((p > 0.05)\).

Factors associated with MetS in patients with AS

In univariate analysis, MetS was significantly associated with age \(> 40\) and BMI \(> 23\). Conversely, gender, smoking, disease duration, the number of SynAnk, and disease activity were not associated with MetS (Table 4). In multiple regression analysis, only BMI \(>23 (p < 0.001)\) and age \(> 40 (p = 0.01)\) were significantly and independently associated with MetS in AS patients.

Factors associated with MetS stratified by gender

Interestingly, female patients with PsA had a significantly higher prevalence of MetS \([47 (52.8\%) \text{ vs. } 25 (32.5\%), p = 0.008]\) and a lower median [inter quartile range (IQR)] number of SynAnk \([2.0 (8.0) \text{ vs. } 5.0 (6.5), p = 0.006]\) than male patients with PsA. Conversely, the prevalence of MetS in male patients with AS \(22.3\%\) was higher than in female patients \(13.6\% (p = 0.177)\).

Men with AS also had a significantly higher median (IQR) number of SynAnk \([4 (15) \text{ vs. } 0 (4), p < 0.001]\) and a longer median (IQR) disease duration \([10 (14.0) \text{ vs. } 6.0 (9.0) \text{ years}, p = 0.006]\) than women with AS. As a result, variables of interest from our analysis of the entire study cohort were further analyzed stratified by gender.

In the female subgroup, age \(> 40\), PsA, BMI \(> 23\), and the number of SynAnk were significantly associated with MetS, while ASDAS-CRP \(> 2.1\) had marginal association in univariate analysis (Table 5). Conversely, disease duration \(> 10\) years and smoking were not associated with MetS. In multiple regression analysis, only BMI \(> 23 (p < 0.001)\) and age \(> 40 (p = 0.037)\) were significantly associated with MetS.

Regarding univariate analysis in male subgroup, BMI \(> 23\), age \(> 40\), and the number of SynAnk were significantly associated with MetS, while PsA had marginal association. ASDAS-CRP \(> 2.1\), disease duration \(> 10\) years, and smoking were not associated with MetS. In multiple regression analysis, only BMI \(> 23 (p < 0.001)\) and age \(> 40 (p = 0.037)\) were significantly associated with MetS.

**Discussion**

Several studies have reported association between PsA and MetS \([10, 14–16, 29]\), while the relationship between MetS and AS is not as strong \([15, 19, 30]\). We

---

**Table 1** Participant characteristics compared between the ankylosing spondylitis and psoriatic arthritis groups

| Characteristics | All \((n = 319)\) | Ankylosing spondylitis \((n = 153)\) | Psoriatic arthritis \((n = 166)\) | \(p\)-value† |
|-----------------|-----------------|-------------------------------|---------------------------------|--------------|
| Age (yrs), mean ± SD       | 45.5 ± 12.2     | 41.7 ± 11.2                   | 49.0 ± 12.1                     | <0.001       |
| Female gender, n (%)      | 148 (46.4%)     | 59 (38.6%)                    | 89 (53.6%)                      | 0.007        |
| Disease duration (yrs), median (IQR) | 5.0 (8.0) | 10.0 (15.0)                  | 3.0 (5.8)                       | <0.001       |
| Hypertension, n (%)       | 71 (22.3%)      | 25 (16.3%)                    | 46 (27.7%)                      | 0.015        |
| Diabetes, n (%)           | 34 (10.7%)      | 6 (3.9%)                      | 28 (16.9%)                      | <0.001       |
| Dyslipidemia, n (%)       | 54 (16.9%)      | 18 (11.8%)                    | 36 (21.7%)                      | 0.018        |
| Current smoker, n (%)     | 27 (8.5%)       | 12 (7.8%)                     | 15 (9.0%)                       | 0.702        |
| Ex-smoker, n (%)          | 28 (8.8%)       | 10 (6.5%)                     | 18 (10.8%)                      | 0.240        |
| Current exercise, n (%)   | 134 (42.0%)     | 70 (45.8%)                    | 64 (38.6%)                      | 0.193        |
| Occupational physical work, n (%) | 122 (38.2%) | 49 (32.0%)                   | 73 (44.0%)                      | 0.028        |
| BMI (kg/m²), mean ± SD    | 24.4 ± 4.9      | 23.4 ± 4.9                   | 25.3 ± 4.7                      | 0.001        |
| ASDAS-CRP, mean ± SD      | 2.1 ± 1.1       | 2.1 ± 1.1                     | 1.9 ± 1.1                       | 0.993        |
| No. of SynAnk, median (IQR) | 3.0 (8.5) | 2.5 (11.0)                  | 4.0 (8.0)                       | 0.755        |
| Current DMARDs, median (IQR) | 1.0 (0)  | 1.0 (1.0)                    | 1.0 (1.0)                       | 0.424        |
| Current NSAIDs, n (%)     | 115 (36.1%)     | 34 (33.7%)                    | 81 (37.2%)                      | 0.546        |

* A \(p\)-value < 0.05 indicates statistical significance
* †Reflects comparison between ankylosing spondylitis and psoriatic arthritis

**Abbreviations**: SD Standard deviation; IQR Interquartile range; BMI Body mass index; ASDAS-CRP Ankylosing Spondylitis Disease Activity - C-reactive protein; SynAnk Syndesmophyte or ankylosis; DMARDs Disease-modifying antirheumatic drugs; NSAIDs Non-steroidal anti-inflammatory drugs.
Table 2 Characteristics compared between those with and without metabolic syndrome further compared among all included patients, ankylosing spondylitis patients, and psoriatic arthritis patients

| Characteristics | All (n = 319) | | | Ankylosing spondylitis (n = 153) | | | Psoriatic arthritis (n = 166) | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Metabolic syndrome** | Yes (n = 101) | No (n = 218) | Yes (n = 29) | No (n = 124) | Yes (n = 72) | No (n = 94) |
| Number of MetS criteria, median (IQR) | 4.0 (1.0) | 1.0 (2.0)* | 4.0 (1.0) | 1.0 (2.0)* | 3.5 (1.0) | 1.0 (2.0)* |
| Elevated WC, n (%) | 93 (29.1%) | 60 (27.5%)* | 24 (82.8%) | 28 (22.6%)* | 63 (87.5%) | 27 (28.7%)* |
| Elevated BP, n (%) | 87 (27.6%) | 55 (25.2%)* | 24 (82.8%) | 28 (22.6%)* | 63 (87.5%) | 27 (28.7%)* |
| Elevated FG, n (%) | 74 (23.3%) | 38 (17.4%)* | 23 (79.3%) | 13 (10.5%)* | 51 (70.8%) | 25 (26.6%)* |
| Elevated TG, n (%) | 50 (16.0%) | 20 (9.2%)* | 12 (41.4%) | 12 (9.7%)* | 38 (52.8%) | 8 (8.5%)* |
| Reduced HDL-C, n (%) | 63 (20.0%) | 26 (11.9%)* | 21 (72.4%) | 12 (9.7%)* | 69 (95.8%) | 26 (27.7%)* |
| Age (yrs), mean ± SD | 52.3 ± 10.1 | 42.3 ± 11.9* | 48.0 ± 9.2 | 40.3 ± 11.2* | 54.0 ± 9.9 | 45.1 ± 12.3* |
| Female gender, n (%) | 55 (54.5%) | 93 (42.7%)* | 8 (27.6%) | 51 (41.1%) | 47 (65.3%) | 42 (44.7%)* |
| History of smoking, n (%) | 13 (12.9%) | 42 (19.3%) | 4 (13.8%) | 18 (14.5%) | 9 (12.5%) | 24 (25.5%)* |
| Current smoker, n (%) | 5 (5.0%) | 22 (10.1%) | 3 (10.3%) | 9 (7.3%) | 2 (2.8%) | 13 (13.8%)* |
| Current exercise, n (%) | 40 (39.6%) | 94 (43.1%) | 9 (31.0%) | 40 (49.2%) | 31 (43.1%) | 33 (35.1%) |
| Physical work, n (%) | 37 (36.6%) | 85 (39.0%) | 8 (27.6%) | 41 (33.1%) | 29 (40.3%) | 44 (46.8%)* |
| BMI (kg/m²), mean ± SD | 27.2 ± 6.0 | 23.1 ± 4.5* | 27.0 ± 4.5 | 22.5 ± 4.6* | 27.3 ± 4.5 | 23.7 ± 4.3* |
| Disease duration (yrs), median (IQR) | 5.0 (8.0) | 5.0 (9.0) | 10.0 (14.5) | 10 (13.8) | 3.0 (6.5) | 3.0 (4.6) |
| ASDAS-CRP, mean (SD) | 2.0 (1.1) | 2.2 (1.1) | 2.0 (1.1) | 2.2 (1.1) | 2.0 (1.1) | 2.3 (1.2) |
| cDAPSA, median (IQR) | N/A | N/A | N/A | N/A | 6.3 (10.5) | 9.1 (12) |
| DAPSA, median (IQR) | N/A | N/A | N/A | N/A | 6.0 (9.5) | 8.0 (11) |
| No. of SynAnk, median (IQR) | 5.5 (8.0) | 2.0 (7.0)* | 5.0 (11.5) | 2.0 (10.0)* | 6.0 (9.0) | 2.0 (5.0)* |
| Current DMARDs, median (IQR) | 1.0 (1.5) | 1.0 (0) | 1.0 (1.5) | 1.0 (1.0) | 1.0 (1.0) | 1.0 (0.25) |
| Current NSAIDs, n (%) | 34 (33.7%) | 81 (37.2%) | 12 (41.3%) | 53 (42.7%) | 22 (30.6%) | 28 (29.8%)* |
| *Indicates a p-value < 0.05 |

Abbreviations: MetS Metabolic syndrome; IQR Interquartile range; WC Waist circumference; BP Blood pressure; FG Fasting glucose; TG Triglycerides; HDL-C High-density lipoprotein cholesterol; SD Standard deviation; BMI Body mass index; ASDAS-CRP Ankylosing Spondylitis Disease Activity - C-reactive protein; cDAPSA Clinical Disease Activity Index for Psoriatic Arthritis; DAPSA Disease Activity Index for Psoriatic Arthritis; SynAnk Syndesmophyte or ankylosis; DMARDs Disease modifying antirheumatic drugs; NSAIDs Non-steroidal anti-inflammatory drugs, N/A Not applicable

Table 3 Univariate and multiple logistic regression analyses for factors significantly associated with metabolic syndrome in patients with psoriatic arthritis

| Factors | Univariate analysis OR 95% CI | Multiple regression analysis OR 95% CI |
| --- | --- | --- |
| Age ≥ 40 years | 5.41* 2.12–13.85 | 2.98 0.93–9.50 |
| Female gender | 2.33* 1.24–4.38 | 3.85* 1.45–10.22 |
| History of smoking | 0.42* 0.18–0.96 | 0.54 0.16–1.83 |
| BMI ≥ 23 kg/m² | 4.04* 1.92–8.48 | 3.67* 1.40–9.60 |
| Disease duration ≥10 years | 1.63 0.74–3.61 | 1.64 0.57–4.74 |
| No. of SynAnk | 1.12* 1.05–1.19 | 1.14* 1.05–1.23 |
| cDAPSA > 13 | 0.69 0.33–1.46 | N/A N/A |
| DAPSA > 14 | 0.62 0.29–1.35 | 0.42 0.16–1.10 |
| ASDAS-CRP ≥ 2.1 | 0.61** 0.3–1.24 | N/A N/A |

*Indicates a p-value < 0.05; **Indicates a p-value from 0.05 to < 0.2

Abbreviations: OR Odds ratio; CI Confidence interval; BMI Body mass index; SynAnk Syndesmophyte or ankylosis; cDAPSA Clinical Disease Activity Index for Psoriatic Arthritis; DAPSA Disease Activity Index for Psoriatic Arthritis; ASDAS-CRP Ankylosing Spondylitis Disease Activity – C-reactive protein; N/A Not applicable
observed a high prevalence of MetS in Thai patients with PsA (43.4%). In contrast, the prevalence of MetS in AS patients was 19.0%, which is comparable to the prevalence rate in the 35–45 age group (10–20% for men, and 23% for women); however, it is considerably lower than the 32.6% prevalence of MetS in overall general population in Thailand [31]. A study from Hong Kong reported a prevalence of MetS was increased in patients with PsA of 38% while it was not increased in patients with AS [15].

BMI is significantly associated with MetS in the general population [32]. BMI was also found to be strongly associated with MetS in our patients with AS or PsA, which is consistent with other published findings [15, 17]. Age was associated with MetS only in patients with AS in the present study, which is similar to the finding of Papadakis, et al. [18]. The association between age and MetS in PsA is unclear [16, 33]. Increasing age and female gender were reported to be associated with MetS in the general population in Europe [34] and in Thailand.

Table 4 Univariate and multiple logistic regression analyses for factors significantly associated with metabolic syndrome in patients with ankylosing spondylitis

| Variables | Univariate analysis | Multiple regression analysis |
|-----------|---------------------|-----------------------------|
|           | OR                  | 95% CI                      | OR                  | 95% CI                      |
| Age > 40  | 4.09*               | 1.56–10.73                  | 4.31*               | 1.43–13.01                  |
| Female gender | 0.55               | 0.22–1.33                   | N/A                 | N/A                         |
| History of smoking | 0.94               | 0.29–3.03                   | N/A                 | N/A                         |
| BMI > 23 kg/m² | 8.51*               | 3.03–23.89                  | 9.09*               | 3.13–26.36                  |
| Disease duration > 10 years | 0.88               | 0.54–1.44                   | N/A                 | N/A                         |
| No. of SynAnk | 1.04**               | 0.99–1.09                   | 1.0                 | 0.94–1.06                   |
| ASDAS-CRP > 2.1 | 0.57               | 0.23–1.45                   | N/A                 | N/A                         |

*Indicates a p-value < 0.05; **Indicates a p-value from 0.05 to < 0.2

Abbreviations: OR Odds ratio; CI Confidence interval; SynAnk Syndesmophyte or ankylosis; ASDAS-CRP Ankylosing Spondylitis Disease Activity - C-reactive protein; N/A Not applicable

Table 5 Univariate and multiple logistic regression analyses for factors significantly associated with metabolic syndrome compared between genders among all patients included in this study

| Variables                | Characteristics Metabolic syndrome | Univariate analysis | Multiple regression analysis |
|--------------------------|------------------------------------|---------------------|-----------------------------|
|                          | Yes                  | No                  | OR                  | 95% CI                      | OR                  | 95% CI                      |
| Female gender, n (%)     | 55 (37.2%)            | 93 (62.8%)          | 7.42*               | 3.13–17.57                  | 3.48*               | 1.14–10.60                  |
| Psoriatic arthritis, n (%) | 47 (85.5%)            | 42 (45.2%)          | 9.96*               | 3.62–27.41                  | 2.44                | 0.95–12.48                  |
| Age > 40, n (%)          | 50 (90.9%)            | 48 (51.6%)          | 1.54                | 0.21–11.24                  | N/A                 | N/A                         |
| History of smoking, n (%) | 2 (3.6%)              | 2 (2.2%)            | 4.5*                | 2.12–9.58                   | 3.74*               | 1.31–10.60                  |
| BMI > 23 kg/m², n (%)    | 42 (76.4%)            | 40 (43.0%)          | 0.68                | 0.31–1.49                   | N/A                 | N/A                         |
| Disease duration > 10 years, n (%) | 12 (21.8%)        | 27 (29.0%)          | 1.15*               | 1.06–1.25                   | 1.18*               | 1.05–1.32                   |
| SynAnk, median (IQR)     | 5 (7)                | 0 (3)*              | 0.36*               | 0.16–0.81                   | 0.37                | 0.14–1.01                   |
| ASDAS-CRP ≥ 2.1, n (%)   | 15 (34.1%)            | 36 (52.9%)          | 13 (34.2%)          | 42 (54.3%)                  | 25 (54.3%)          | 52 (41.6%)                  |
| Male gender, n (%)       | 46 (26.9%)            | 125 (73.1%)         | 1.83**              | 0.91–3.68                   | 0.96                | 0.43–2.17                   |
| Psoriatic arthritis, n (%) | 25 (54.3%)            | 52 (41.6%)          | 3.47*               | 1.43–8.45                   | 2.91*               | 1.07–7.93                   |
| Age > 40, n (%)          | 39 (84.8%)            | 75 (60.0%)          | 0.65                | 0.29–1.47                   | N/A                 | N/A                         |
| History of smoking, n (%) | 11 (23.9%)            | 40 (32.0%)          | 13.27*              | 4.45–39.56                  | 11.42*              | 3.75–34.79                  |
| BMI > 23 kg/m², n (%)    | 42 (91.3%)            | 56 (45.5%)          | 1.27                | 0.65–2.51                   | N/A                 | N/A                         |
| Disease duration > 10 years, n (%) | 23 (50.0%)       | 55 (44.0%)          | 1.05*               | 1.01–1.10                   | 1.02                | 0.97–1.08                   |
| SynAnk, median (IQR)     | 7.5 (11)             | 4.0 (11)*           | 0.73                | 0.33–1.61                   | N/A                 | N/A                         |
| ASDAS-CRP ≥ 2.1, n (%)   | 13 (34.2%)            | 43 (44.8%)          | 1.0                 | 0.94–1.06                   | 1.02                | 0.97–1.08                   |

*Indicates a p-value < 0.05; **Indicates a p-value from 0.05 to < 0.2

Abbreviations: OR Odds ratio; CI Confidence interval; SynAnk Number of syndesmophyte or ankylosis; ASDAS-CRP Ankylosing Spondylitis Disease Activity - C-reactive protein; N/A Not applicable
Interestingly, female gender was associated with MetS in PsA, but not with AS in our study. Thus, we further investigated for association between evaluated factors and MetS stratified by gender. That analysis revealed that PsA patients are more likely to have MetS than AS patients in the female subgroup. In contrast, patients with PsA or AS had a comparable likelihood of having MetS in the male subgroup. Eder et al. [35] reported the level of leptin, which is an adipokine that is associated with obesity [36], to be higher in female patients with PsA than in those with psoriasis, but it was comparable in men [35]. Gender may affect dysregulation of adipokines differently in each inflammatory disease. Moreover, gender has a different effect on the clinical characteristics and severity of AS [37] and PsA [38]. Males demonstrated more rapid radiographic progression compared to females with AS [37], while male patients with PsA had a more favorable clinical outcome than females [38].

In this study, Thai female patients with PsA had a significantly higher prevalence of MetS (52.8%) than men (32.8%); however, they had a lower proportion of SynAnk. Conversely, the prevalence of MetS in male patients with AS was higher than in female patients, although that difference was not statistically significant. Male patients with AS had longer disease duration and greater structural spinal change than female patients. New bone formation in the spine in AS was associated with resolution of spinal inflammation [39]. Therefore, the presence of SynAnk in AS patients may reflect previous inflammation. A higher number of SynAnk, therefore, suggests a greater degree of previous inflammation. Unfortunately, this study was a cross-sectional study, and our sample of AS patients with MetS was too small to permit further analysis.

The presence of SynAnk was significantly associated with MetS in patients with PsA in the present study. This is similar to a study by Haroon and colleagues that found radiographic damage on peripheral or sacroiliac joints and requirement for tumor necrosis factor inhibitor (TNFi) among PsA to be significantly associated with MetS [17]. Interestingly, disease activity index was not associated with MetS in this study. Active joint inflammation was reported to be associated with decreases in serum lipid levels in rheumatoid arthritis and PsA patients [13, 40, 41]. Highly active disease may also result in weight loss [13]. However, the association between current disease activity and MetS in patients with spondyloarthritis remains controversial [17, 33, 40]. Most studies, including the present study, applied a cross-sectional design, and this makes it difficult to determine the duration of persistent active inflammation. Spondyloarthritis is a chronic inflammatory disease, but inflammation levels may fluctuate [42]. Thus, the presence of structural changes of the spine may be more suitable for determining the long-term course of inflammation than disease status activity index. Consistent with that, in addition to the traditional risk factors for MetS, patients with structural spinal changes were more likely to have MetS among PsA and AS patients in our study.

The association between smoking and MetS is not clear [43]. In our study, smoking was negatively associated with MetS in PsA patients in univariate analysis; however, smoking did not remain statistically significant after adjustment for other variables. Men were more likely to smoke than women among patients with PsA [30 (39%) vs. 3 (3.4%), p < 0.001]. Moreover, male gender was found to be strongly negatively associated with MetS in PsA patients after adjustment for other factors, including smoking. Therefore, the association between smoking and MetS in PsA patients only in univariate analysis may be influenced by male gender.

This study has some limitations. First, the cross-sectional design does not permit exploration of changes in disease over time. Our measurements of disease activity could not assess the duration of activity of disease over time. Therefore, our results may not reflect the long-term course of the disease, except to the extent that structural changes of the spine are the result of chronic inflammation. Second, we did not have an age- and gender-matched control group. A control group is needed to better understand the contribution of specific risk factors. Third, our study had a small number of AS patients with MetS, which limited our ability to conduct subgroup analysis. Fourth, our participants came from a single tertiary care hospital, so our results may not be generalizable to other care settings and to a larger population of Thai PsA and AS patients. Fifth, some participants did not perform CRP, so there was no ASDAS-CRP or DAPSA assessment. However, our study included other disease status indexes (cDAPSA), and the results were comparable (data not shown). Sixth and last, radiographic change was determined by one rheumatologist who is a well-trained reader. However, the use of two well-trained interpreters may have yielded more accurate assessments of radiographic change. Syn-desmophyte and intervertebral ankylosis which were irreversible lesions were counted as radiographic change in this study. They may be less sensitive to detect structural change than the Modified Ankylosing Spondylitis Spine Score. Diffuse idiopathic skeletal hyperostosis (DISH) which is strongly associated with the metabolic syndrome is characterized by chunky bridging osteophyte [44]. An early DISH lesion may be interpreted as syndesmophyte although most lesions can be differentiated. A strength of this study is that we used the Harmonized definition of MetS, which is suitable for use in Asian populations.
Conclusion

MetS was significantly more prevalent in PsA than in AS. Female, BMI ≥ 23 and structural change of the spine were associated with MetS in PsA. Traditional factors (BMI ≥ 23 and age ≥ 40) were associated with MetS in AS patients. Female patients with PsA were more likely to have MetS than male patients with PsA and female patients with AS. Patients with PsA or AS should be advised to maintain their BMI < 23 kg/m². In addition to traditional factors of MetS, evidence of structural spinal change should be informed to screen for MetS among PsA patients.

Abbreviations

AS: Ankylosing spondylitis; ASDAS-CRP: The ankylosing spondylitis disease activity score; C-Reactive protein; BASDAI: The bath ankylosing spondylitis disease activity index; BMI: Body mass index; BP: Blood pressure; cDAPSA: Clinical disease activity index for psoriatic arthritis; CRP: C-Reactive protein; CVD: Cardiovascular disease; DAPSA: The disease activity index for psoriatic arthritis; DBP: Diastolic blood pressure; DMARDs: Disease modifying anti-rheumatic drugs; FG: Fasting glucose; HDL-C: High-density lipoprotein cholesterol; MetS: Metabolic syndrome; NSAIDs: Non-steroidal anti-inflammatory drugs; PGA: Patient global assessment; PP: Patient pain; PsA: Psoriatic arthritis; SJC: Swollen joint count; SpA: Spondyloarthritis; SynAnk: Syndesmophyte or ankylosis; TG: Triglycerides; TJC: Tender joint count; WC: Waist circumference

Acknowledgements

The authors gratefully acknowledge the participation and cooperation of the patients who were enrolled in this study; Dr. Naphruet Limsakul, Ms. Nutwara Meannui, and Ms. Kamolnate Thaweeratthakul for their assistance with data collection; and, Ms. Khemajira Karaketklang and Dr. Chulaluk Komoltri for their assistance with statistical analysis.

Authors’ contributions

CP and PC conceived and designed the study, analyzed data and drafted this manuscript. VS contributed to analysis of the data, and revising of the manuscript. All authors have read and approved the final manuscript.

Funding

This research was supported by grants from the Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University (grant numbers R015731046 and R015533011). CP received a grant from the Thai Rheumatism Association. The granting agencies had no role in any aspect of the study, the development of the manuscript, or the journal submission process.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Siriraj Institutional Review Board (SIRB) (COA no. Si 147/2014). Written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that have any influence on the work reported in this paper.

Author details

1Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand. 2Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Received: 19 January 2021 Accepted: 31 March 2021

Published online: 20 April 2021

References

1. Sikora K, Layh-Schmitt G, Colbert R. Etiology and pathogenesis of spondyloarthritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes I, O’Dell J, editors. Kelly’s textbook of rheumatology. 2. 10th ed. Philadelphia: Elsevier; 2017. p. 1245–55. https://doi.org/10.1016/B978-0-323-31696-5.00074-7.

2. Castaneda S, Nurmohamed MT, Gonzalez-Gay MA. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2016;30(5):851–69. https://doi.org/10.1016/j.berh.2016.10.006.

3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Zimmet LY, Lean ME, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the study of obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.106244.

4. Molto A, Nikiforou E. Comorbidities in Spondyloarthritis. Front Med (Lausanne). 2018;5:62. https://doi.org/10.3389/fmed.2018.00062.

5. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57(2):287–93. https://doi.org/10.1002/art.22530.

6. Yuan Y, Yang J, Zhang X, Han R, Chen M, Hu X, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic review and updated meta-analysis. J Atheroscler Thromb. 2019;26(3):260–71. https://doi.org/10.5551/jat.45294.

7. Horneau C, Pouplard B, Brenaut E, Bametche T, Misyat L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12–29. https://doi.org/10.1111/jdv.12163.

8. Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum. 2015;44(5):551–5. https://doi.org/10.1016/j.semarthrit.2014.10.007.

9. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes IB, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–6. https://doi.org/10.1136/annrheumdis-2011-209775.

7. https://doi.org/10.1002/acr.20363.

8. Atkinson A, Fool, Peters MJ, Sattar N, McInnes IB, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–6. https://doi.org/10.1136/annrheumdis-2011-209775.

9. Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum. 2015;44(5):551–5. https://doi.org/10.1016/j.semarthrit.2014.10.007.

10. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes IB, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–6. https://doi.org/10.1136/annrheumdis-2011-209775.

11. Haroon NN, Paterson JM, Li P, Imnan RD, Haroon N. Patients with Ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163(6):409–16. https://doi.org/10.7326/M14-2470.

12. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7. https://doi.org/10.1038/nature05485.

13. Kerekes G, Nurmohamed MT, Gonzalez-Gay MA, Seres I, Paragh G, Kardos Z, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10(11):691–7. https://doi.org/10.1038/nrrheum.2014.121.

14. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jalal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8(4):331–6. https://doi.org/10.1089/nnr.2009.0124.

15. Mox CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63(2):195–202. https://doi.org/10.1002/acr.20363.

16. Sharma A, Gopalakrishnan D, Kumar R, Vijayvergiya R, Dogra S. Metabolic syndrome in psoriatic arthritis patients: a cross-sectional study. Int J Rheum Dis. 2013;16(6):667–73. https://doi.org/10.1111/1756-185X.12134.
17. Haroon M, Gallagher P, Heffeman E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014;41(7):1357–65. https://doi.org/10.3899/jrheum.140021.

18. Papadakis JA, Sidiropoulos PI, Kanourantis SA, Vrentzos GE, Spanakis EK, Giatromanolaki A, et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol. 2009;27(2):292–8.

19. Malecchi D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol. 2007;26(5):710–4. https://doi.org/10.1007/s00296-006-0980-5.

20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8. https://doi.org/10.1002/art.1780270401.

21. Taylor W, Gladman D, Helliwell P, Marcheson A, Mease P, Melants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73. https://doi.org/10.1002/art.21972.

22. Kittipanyapana C, Chaiamnuay S, Asavatananobdee P, Narongroeknawin P. Reliability and validity of the Thai version of bath ankylosing spondylitis indices. J Med Assoc Thail. 2014;97(4):381–5.

23. Jih J, Mukherjee A, Vittinghoff E, Nguyen TT, Tsoh JY, Fukuoka Y, et al. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. Prev Med. 2014;65:1–6. https://doi.org/10.1016/j.ypmed.2014.01.010.

24. Machado P, Landewe R, Liee E, Kvien TK, Braun J, Baker D, et al. Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(7):47–53. https://doi.org/10.1136/ard.2010.185994.

25. Smolen JS, Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, et al. Development and validation of the DARE/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441–7. https://doi.org/10.1136/ard.2009.122259.

26. Smolen JS, Schoels M, Aletaha D. Disease activity and response assessment in psoriatic arthritis using the disease activity index for Psoriatic arthritis (DAPSA). A brief review. Clin Exp Rheumatol. 2015;33(Suppl 93):S548–50.

27. Maksymowych WP, Leach T, Lambert RS, Ward M, Haroon N, Inman R, et al. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol. 2011;38(7):1349–54. https://doi.org/10.3899/jrheum.100925.

28. Lazariev MB, Utic J, Mladenovic V, Myones BL, Skosey JL, Swedler W. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum. 1992;22(3):172–8. https://doi.org/10.1016/0049-0172(92)90017-8.

29. Cho Y, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68(4):460–9. https://doi.org/10.1136/ard.2008.101964.

30. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 2008;58(3):649–56. https://doi.org/10.1002/art.23260.

31. Perez-Martinez P, Mikhaelidis DP, Athyros VG, Bullo M, Couture P, Covas MI, et al. Cardiovascular morbidity and associated risk factors in Asian Americans. Prev Med. 2014;65:1–5. https://doi.org/10.1016/j.ypmed.2014.01.002.

32. Groene F, Lopez-Mejias R, Miranda-Forero JA, Ubbilla B, Camero-Lopez B, Blanco R, et al. Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. Biom Res Int. 2014;2014:680651.

33. Aekplakon W, Chongsuvivatwong V, Tatsanavivat P, Suriyawongpaisal P. Prevalence of metabolic syndrome defined by the international diabetes federation and National Cholesterol Education Program criteria among Thai adults. Asia Pac J Public Health. 2011;23(5):792–800. https://doi.org/10.1177/1010539511424482.

34. Savva SC, Lannitos D, Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI? A meta-analysis. Diabetes Metab Syndr Obes. 2013;6:303–19. https://doi.org/10.2147/DMSO.S54520.

35. Pehlevan S, Yetkin DO, Bahadir C, Goktan F, Pehlevan Y, Kayatas K, et al. Increased prevalence of metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2014;12(1):43–8. https://doi.org/10.1089/ mets.2013.0039.

36. Vithram JK, Borglykke A, Andreassen AH, Jeppesen J, Ibsen H, Jorgensen T, et al. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM prospective cohort project. PloS one. 2014;9:e107294.

37. Eder L, Jayakar J, Pollack R, Pellett F, Thavaneswaran A, Chandran V, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. 2015;74(12):1956–61. https://doi.org/10.1136/annrheumdis-2012-202325.

38. Ouchi N, Parker JL, Luxus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97. https://doi.org/10.1038/nri2921.

39. Baralakos X, Listing J, von der Recke A, Braun J. The natural course of radiographic progression in Ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features. Curr Rheumatol Rep. 2011;13(5):388–7. https://doi.org/10.1007/s11926-011-0192-8.

40. Theander E, Husmark T, Aulinius GM, Larsson PT, Telemann A, Geijer M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish early psoriatic arthritis register (SwePSa). Ann Rheum Dis. 2014;73(3):407–13. https://doi.org/10.1136/annrheumdis-2012-201972.

41. Pedersen SJ, Chowchanwisawat P, Lambert RG, Oestgaard M, Maksymowych WP. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol. 2011;38(7):1349–54. https://doi.org/10.3899/jrheum.100925.

42. Lazarevic MB, Utic J, Mladenovic V, Myones BL, Skosey JL, Swedler W. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum. 1992;22(3):172–8. https://doi.org/10.1016/0049-0172(92)90017-8.

43. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68(4):460–9. https://doi.org/10.1136/ard.2008.101964.

44. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 2008;58(3):649–56. https://doi.org/10.1002/art.23260.

45. Perez-Martinez P, Mikhaelidis DP, Athyros VG, Bullo M, Couture P, Covas MI, et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutr Rev. 2017;75(5):307–26. https://doi.org/10.1093/nutrit/nux014.

46. Mader R, Baralakos X, Eshed I, Novofastovski I, Bieber A, Verlaan JJ, et al. Imaging of diffuse idiopathic skeletal hyperostosis (DISH). RMD Open. 2020; 6(1):e001151. https://doi.org/10.1136/rmdopen-2019-001151.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.